Form 4: Stoke Therapeutics CEO Edward M. Kaye Sells Shares Under 10b5-1 Trading Plan

Stoke Therapeutics CEO Edward M. Kaye sold shares of common stock on May 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 20, 2024, Edward M. Kaye, CEO of Stoke Therapeutics, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 26, 2023.
• A total of 42,350 shares were sold in multiple transactions at weighted average prices of $15.3904 and $16.0457.
• Following the reported transactions, Kaye directly owns 27,000 shares of Stoke Therapeutics common stock.
• Kaye has granted a Limited Power of Attorney to Jonathan Allan and Thomas Leggett to execute and file Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. The sentiment is neutral as it simply reports transactions.

Risks

• Sales by insiders, even under 10b5-1 plans, can sometimes be perceived negatively by the market.

Industry Context

Insider trading activity is common, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-planned. Investors often monitor insider transactions for signals about a company's prospects.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment.

Key Dates